Literature DB >> 6881590

Use of a fentanyl infusion in the intensive care unit: tolerance to its anesthetic effects?

A Shafer, P F White, J Schüttler, M H Rosenthal.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6881590

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


× No keyword cloud information.
  7 in total

Review 1.  Assisted ventilation. 3. General care of the ventilated patient in the intensive care unit.

Authors:  M R Hamilton-Farrell; G C Hanson
Journal:  Thorax       Date:  1990-12       Impact factor: 9.139

2.  Withdrawal following sufentanil/propofol and sufentanil/midazolam. Sedation in surgical ICU patients: correlation with central nervous parameters and endogenous opioids.

Authors:  Maria Korak-Leiter; Rudolf Likar; Michael Oher; Ernst Trampitsch; Gerda Ziervogel; Joseph V Levy; Enno C Freye
Journal:  Intensive Care Med       Date:  2005-02-16       Impact factor: 17.440

Review 3.  Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

Authors:  B K Wagner; D A O'Hara
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

4.  Outpatient therapy of iatrogenic drug dependency following prolonged sedation in the pediatric intensive care unit.

Authors:  J D Tobias; J K Deshpande; D F Gregory
Journal:  Intensive Care Med       Date:  1994-08       Impact factor: 17.440

5.  Epidural and intrathecal morphine in intensive care units.

Authors:  N Rawal; B Tandon
Journal:  Intensive Care Med       Date:  1985       Impact factor: 17.440

Review 6.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

Review 7.  Alfentanil infusions in patients requiring intensive care.

Authors:  A Bodenham; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.